Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients

Aliment Pharmacol Ther. 2017 Nov;46(9):903-905. doi: 10.1111/apt.14262.

Authors

G Fiorino¹, C Correale¹, S Radice¹, M Allocca¹, F Furfaro¹, D Gilardi¹, D Nagore², L Del Rio², J Pascual², A Martínez², S Danese^{1

3}

Affiliations

¹ Department of Gastroenterology, IBD Centre, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
² R&D Department, Progenika SA, Derio, Spain.
³ Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.

PMID: 29023889
DOI: 10.1111/apt.14262

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal*
Biosimilar Pharmaceuticals
Humans
Inflammatory Bowel Diseases
Infliximab*

Substances

Antibodies, Monoclonal
Biosimilar Pharmaceuticals
CT-P13
Infliximab